Published in Clin Infect Dis on April 24, 2013
Colistin and Rifampicin for MDR-Acinetobacter (CoRAb) | NCT01577862
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis (2016) 2.08
Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care (2015) 1.30
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother (2014) 1.19
Challenges to conducting a clinical trial of combination therapy of colistin and rifampicin for extensively drug-resistant Acinetobacter baumannii. Clin Infect Dis (2013) 1.08
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs (2014) 1.06
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens. Infect Chemother (2014) 1.01
Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis (2014) 1.00
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 0.99
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med (2015) 0.99
Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis (2014) 0.98
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother (2015) 0.97
The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol (2015) 0.92
Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections. Chonnam Med J (2014) 0.91
Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis. PLoS One (2014) 0.90
Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore) (2014) 0.88
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases (2014) 0.88
The potential risks of expedited approval of drugs for acute bacterial infections. JAMA Intern Med (2014) 0.88
Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy (2015) 0.86
New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies. Mediterr J Hematol Infect Dis (2015) 0.85
In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii. Front Microbiol (2015) 0.83
Molecular Epidemiology and Clinical Impact of Acinetobacter calcoaceticus-baumannii Complex in a Belgian Burn Wound Center. PLoS One (2016) 0.83
How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis (2014) 0.81
Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control (2015) 0.81
Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review. J Res Pharm Pract (2015) 0.80
Is there really no benefit to combination therapy with colistin? Expert Rev Anti Infect Ther (2013) 0.79
Current concepts in combination antibiotic therapy for critically ill patients. Indian J Crit Care Med (2014) 0.79
The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infect Dis (2015) 0.78
Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrob Agents Chemother (2016) 0.78
Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms (2016) 0.78
Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge. World J Gastroenterol (2014) 0.78
In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2016) 0.77
Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time? Crit Care Med (2015) 0.77
Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep (2015) 0.76
Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clin Microbiol Rev (2016) 0.76
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev (2017) 0.76
Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis (2016) 0.76
Synergistic combinations of polymyxins. Int J Antimicrob Agents (2016) 0.75
Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. Eur J Clin Microbiol Infect Dis (2016) 0.75
Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis (2017) 0.75
Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient. Transpl Infect Dis (2015) 0.75
Reply to Huang et al. Clin Infect Dis (2013) 0.75
Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerg Microbes Infect (2016) 0.75
Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture. Antimicrob Agents Chemother (2016) 0.75
Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect Dis Ther (2015) 0.75
Editorial commentary: rifampicin plus colistin in the era of extensively drug-resistant Acinetobacter baumannii infections. Clin Infect Dis (2013) 0.75
Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. J Microbiol (2017) 0.75
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections. Infect Dis Ther (2017) 0.75
Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist (2017) 0.75
Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med (2009) 7.82
Prosthetic joint infection: recent developments in diagnosis and management. J Infect (2010) 4.96
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis (2004) 4.26
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Randomized evidence for reduction of perioperative mortality. J Cardiothorac Vasc Anesth (2012) 3.07
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA (2010) 2.77
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol (2005) 2.36
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2009) 2.30
Effects of recruiting maneuvers in patients with acute respiratory distress syndrome ventilated with protective ventilatory strategy. Anesthesiology (2002) 2.27
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer (2005) 2.15
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol (2002) 1.87
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis (2008) 1.71
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer (2005) 1.66
High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis (2011) 1.65
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2009) 1.64
Risk factors for "major" embolic events in hospitalized patients with infective endocarditis. Am Heart J (2003) 1.64
Surgical site infection - a European perspective of incidence and economic burden. Int Wound J (2004) 1.61
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One (2008) 1.56
Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol (2011) 1.54
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Aminoglycosides versus bacteria--a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci (2007) 1.49
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
Do we still need the aminoglycosides? Int J Antimicrob Agents (2008) 1.45
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol (2012) 1.43
Prevalence and significance of two major inherited thrombophilias in infective endocarditis. Intern Emerg Med (2015) 1.42
Schistosomiasis Screening of Travelers from Italy with Possible Exposure in Corsica, France. Emerg Infect Dis (2015) 1.42
Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol (2008) 1.38
Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis (2008) 1.37
High prevalence of intramural coronary infection in patients with drug-resistant cardiac syndrome X: comparison with chronic stable angina and normal controls. Heart (2010) 1.37
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J Antimicrob Chemother (2011) 1.31
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother (2011) 1.29
Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis (2012) 1.27
Detection and investigation of invasive mould disease. J Antimicrob Chemother (2011) 1.27
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J (2006) 1.25
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant (2009) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob (2009) 1.24
Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J Antimicrob Chemother (2010) 1.23
Ocular manifestations of candidemia. Clin Infect Dis (2011) 1.22
Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. J Antimicrob Chemother (2006) 1.21
Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin Investig Drugs (2008) 1.21
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother (2013) 1.18
Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother (2011) 1.18
A case of secondary syphilis presenting as optic neuritis. Neurol Sci (2010) 1.17
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis (2007) 1.17
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet (2010) 1.16
Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med (2008) 1.16
End-of-life decision-making and quality of ICU performance: an observational study in 84 Italian units. Intensive Care Med (2010) 1.16
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis (2002) 1.15
Reversion to susceptibility of a carbapenem-resistant clinical isolate of Klebsiella pneumoniae producing KPC-3. J Antimicrob Chemother (2013) 1.15
Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther (2013) 1.13
Genome organization of epidemic Acinetobacter baumannii strains. BMC Microbiol (2011) 1.12
Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med (2015) 1.12
Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia (2009) 1.10
Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone. J Clin Microbiol (2010) 1.10
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.10
Phylogenetic analysis of viridans group streptococci causing endocarditis. J Clin Microbiol (2008) 1.10
Critically ill migrants with infection: diagnostic considerations for intensive care physicians in Europe. Intensive Care Med (2016) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 1.08
Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents (2007) 1.08
Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78. BMC Infect Dis (2013) 1.08
Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii strains in intensive care units of multiple Mediterranean hospitals. J Antimicrob Chemother (2009) 1.07
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature. AIDS Patient Care STDS (2010) 1.06
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer (2010) 1.06
Helicobacter pylori gamma-glutamyltranspeptidase upregulates COX-2 and EGF-related peptide expression in human gastric cells. Cell Microbiol (2004) 1.06
Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med (2003) 1.06
Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study. BMC Infect Dis (2013) 1.06
Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis (2010) 1.05
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res (2003) 1.04
Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol (2011) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04